A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)

Marc C. Chamberlain, Sean Grimm, Surasak Phuphanich, Larry Recht, Jay Z. Zhu, Lyndon Kim, Steven Rosenfeld, Camilo E. Fadul

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m2 as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14 % and the PFS-1 for Group 2 was 20 %. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10 % in Group 1; n = 1; 4.2 % in Group 2) and stable disease (n = 7; 23 % in Group 1; n = 5; 21 % in Group 2). In Group 1, 38.7 % of patients experienced a serious adverse event; however only 3.2 % were potentially attributable to study drug. In Group 2, 44 % of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM.

Original languageEnglish (US)
Pages (from-to)335-343
Number of pages9
JournalJournal of Neuro-Oncology
Volume118
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Glioblastoma
Brain Neoplasms
Prospective Studies
Disease-Free Survival
Medical Futility
Intravenous Infusions
Microtubules
Pharmaceutical Preparations
Sample Size
Blood Vessels
Appointments and Schedules
Therapeutics
Survival
verubulin
Brain
Bevacizumab

Keywords

  • Bevacizumab naïve/refractory
  • Recurrent glioblastoma
  • Vascular disrupting agent
  • Verubulin (Azixa)

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

A phase 2 trial of verubulin for recurrent glioblastoma : A prospective study by the brain tumor investigational consortium (BTIC). / Chamberlain, Marc C.; Grimm, Sean; Phuphanich, Surasak; Recht, Larry; Zhu, Jay Z.; Kim, Lyndon; Rosenfeld, Steven; Fadul, Camilo E.

In: Journal of Neuro-Oncology, Vol. 118, No. 2, 01.01.2014, p. 335-343.

Research output: Contribution to journalArticle

Chamberlain, Marc C. ; Grimm, Sean ; Phuphanich, Surasak ; Recht, Larry ; Zhu, Jay Z. ; Kim, Lyndon ; Rosenfeld, Steven ; Fadul, Camilo E. / A phase 2 trial of verubulin for recurrent glioblastoma : A prospective study by the brain tumor investigational consortium (BTIC). In: Journal of Neuro-Oncology. 2014 ; Vol. 118, No. 2. pp. 335-343.
@article{6b05a3ec41be4675afd40d224b2ed022,
title = "A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the brain tumor investigational consortium (BTIC)",
abstract = "Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab na{\"i}ve patients (Group 1). Verubulin was administered at 3.3 mg/m2 as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14 {\%} and the PFS-1 for Group 2 was 20 {\%}. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10 {\%} in Group 1; n = 1; 4.2 {\%} in Group 2) and stable disease (n = 7; 23 {\%} in Group 1; n = 5; 21 {\%} in Group 2). In Group 1, 38.7 {\%} of patients experienced a serious adverse event; however only 3.2 {\%} were potentially attributable to study drug. In Group 2, 44 {\%} of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab na{\"i}ve or refractory recurrent GBM.",
keywords = "Bevacizumab na{\"i}ve/refractory, Recurrent glioblastoma, Vascular disrupting agent, Verubulin (Azixa)",
author = "Chamberlain, {Marc C.} and Sean Grimm and Surasak Phuphanich and Larry Recht and Zhu, {Jay Z.} and Lyndon Kim and Steven Rosenfeld and Fadul, {Camilo E.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11060-014-1437-y",
language = "English (US)",
volume = "118",
pages = "335--343",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase 2 trial of verubulin for recurrent glioblastoma

T2 - A prospective study by the brain tumor investigational consortium (BTIC)

AU - Chamberlain, Marc C.

AU - Grimm, Sean

AU - Phuphanich, Surasak

AU - Recht, Larry

AU - Zhu, Jay Z.

AU - Kim, Lyndon

AU - Rosenfeld, Steven

AU - Fadul, Camilo E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m2 as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14 % and the PFS-1 for Group 2 was 20 %. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10 % in Group 1; n = 1; 4.2 % in Group 2) and stable disease (n = 7; 23 % in Group 1; n = 5; 21 % in Group 2). In Group 1, 38.7 % of patients experienced a serious adverse event; however only 3.2 % were potentially attributable to study drug. In Group 2, 44 % of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM.

AB - Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m2 as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14 % and the PFS-1 for Group 2 was 20 %. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10 % in Group 1; n = 1; 4.2 % in Group 2) and stable disease (n = 7; 23 % in Group 1; n = 5; 21 % in Group 2). In Group 1, 38.7 % of patients experienced a serious adverse event; however only 3.2 % were potentially attributable to study drug. In Group 2, 44 % of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM.

KW - Bevacizumab naïve/refractory

KW - Recurrent glioblastoma

KW - Vascular disrupting agent

KW - Verubulin (Azixa)

UR - http://www.scopus.com/inward/record.url?scp=84903900522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903900522&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1437-y

DO - 10.1007/s11060-014-1437-y

M3 - Article

C2 - 24740196

AN - SCOPUS:84903900522

VL - 118

SP - 335

EP - 343

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -